The experience of using ACE inhibitors and Ca channel blockers in the treatment of hypertension in patients with renal cell carcinoma

Renal cell carcinoma (RCC) is one of widely spread urological cancers. It is known that approximately 26% of patients with a history of kidney cancer (KC) may have concomitant coronary artery disease, hypertension, diabetes mellitus and some other systemic diseases, which may lead to nephrosclerotic changes and the development or progression of the existing CRF. The aim of the study. To study the renal function effects of ACE inhibitors (perindopril arginine) in patients with RCC, both as monotherapy and in combination with Ca channel blockers when conducting treatment of concomitant hypertension (HT). Materials and methods. The study enrolled 38 patients with RCC. All patients were diagnosed with RCC for the first time, with their cancer staged according to the TNM International Classification (Т1 N0 M0). Within a month, the use of combination therapy for kidney cancer complicated by Stage І, Degree ІІ hypertension was leading to increases in serum creatinine by 3 µmol/l and by 7 µmol/l in those patients where combination therapy was not used. In the meantime, during the same period, glomerular filtration rate reduced by 5 ml/min/1.73 m2 in patients of the first group and by 15 ml/min/1.73 m2 in patients of the second group

Physiological basis of human longevity: the concept of a cascade of human aging mechanism

The research is devoted to the fundamental issue of medicine and biology - the study of factors limiting the life span of a person. As a model, the system of adaptation of the human body to the forces of natural gravity is chosen, the disadaptation to which manifests itself in falls and everyday injuries. The object of the study was the selection of severe fractures of bone tissue due to fall, taken in the age aspect. Statistical and meta-analytical research methods were used. It is shown that the age-related increase in mortality due to household falls, coming to severe bone fractures, is non-linear and increases in geometric progression. As a result of the coincidence of the age characteristics of bone fragility and age-related kidney function, an assumption is made about the role of involution of the renal tissue in the development of osteoporosis in the elderly and the need for a new approach to the prevention of osteoporosis and domestic injuries

Physiological basis of human longevity: the concept of a cascade of human aging mechanism

The research is devoted to the fundamental issue of medicine and biology - the study of factors limiting the life span of a person. As a model, the system of adaptation of the human body to the forces of natural gravity is chosen, the disadaptation to which manifests itself in falls and everyday injuries. The object of the study was the selection of severe fractures of bone tissue due to fall, taken in the age aspect. Statistical and meta-analytical research methods were used. It is shown that the age-related increase in mortality due to household falls, coming to severe bone fractures, is non-linear and increases in geometric progression. As a result of the coincidence of the age characteristics of bone fragility and age-related kidney function, an assumption is made about the role of involution of the renal tissue in the development of osteoporosis in the elderly and the need for a new approach to the prevention of osteoporosis and domestic injuries

Vitamin D supplementation to treat SARS-CoV-2 positive patients. Evidence from meta-analysis

Background: Vitamin D is a likely candidate for treatment as its immune modulating characteristics have effects on coronavirus disease 2019 (COVID-19) patients. It was  sought herein, to summarize the studies published to date regarding the vitamin D supplementation to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients. Methods: A systematic review and meta-analysis were performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The primary outcome were 14-day and in-hospital mortality reported as an odds ratio (OR) with the associated 95% confidence interval (CI). Results: Eight articles were included in the review with a combined total of 2,322 individual patients, 786 in the vitamin D supplementation group and 1,536 in the control group. The use of vitamin D compared to the group without vitamin D supplementation was associated with a lower 14-day mortality (18.8% vs. 31.3%, respectively; OR = 0.51; 95% CI: 0.12–2.19; p = 0.36), a lower in-hospital mortality (5.6% vs. 16.1%; OR = 0.56; 95% CI: 0.23–1.37; I2 = 74%; p = 0.20), the rarer intensive care unit admission (6.4% vs. 23.4%; OR = 0.19; 95% CI: 0.06–0.54; I2 = 77%; p = 0.002) as well as rarer mechanical ventilation (6.5% vs. 18.9%; OR = 0.36; 95% CI: 0.16–0.80; I2 = 0.48; p = 0.01). Conclusions: Vitamin D supplementation in SARS-CoV-2 positive patients has the potential to positively impact patients with both mild and severe symptoms. As several high-quality randomized control studies have demonstrated a benefit in hospital mortality, vitamin D should be considered a supplemental therapy of strong interest. Should vitamin D prove to reduce hospitalization rates and symptoms outside of the hospital setting, the cost and benefit to global pandemic mitigation efforts would be substantial

Vitamin D supplementation to treat SARS-CoV-2 positive patients. Evidence from meta-analysis

BACKGROUND: Vitamin D is a likely candidate for treatment as its immune modulating characteristics have effects on coronavirus disease 2019 (COVID-19) patients. It was sought herein, to summarize the studies published to date regarding the vitamin D supplementation to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients. METHODS: A systematic review and meta-analysis were performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The primary outcome were 14-day and in-hospital mortality reported as an odds ratio (OR) with the associated 95% confidence interval (CI). RESULTS: Eight articles were included in the review with a combined total of 2,322 individual patients, 786 in the vitamin D supplementation group and 1,536 in the control group. The use of vitamin D compared to the group without vitamin D supplementation was associated with a lower 14-day mortality (18.8% vs. 31.3%, respectively; OR = 0.51; 95% CI: 0.12-2.19; p = 0.36), a lower in-hospital mortality (5.6% vs. 16.1%; OR = 0.56; 95% CI: 0.23-1.37; I2 = 74%; p = 0.20), the rarer intensive care unit admission (6.4% vs. 23.4%; OR = 0.19; 95% CI: 0.06-0.54; I2 = 77%; p = 0.002) as well as rarer mechanical ventilation (6.5% vs. 18.9%; OR = 0.36; 95% CI: 0.16-0.80; I2 = 0.48; p = 0.01). CONCLUSIONS: Vitamin D supplementation in SARS-CoV-2 positive patients has the potential to positively impact patients with both mild and severe symptoms. As several high-quality randomized control studies have demonstrated a benefit in hospital mortality, vitamin D should be considered a supplemental therapy of strong interest. Should vitamin D prove to reduce hospitalization rates and symptoms outside of the hospital setting, the cost and benefit to global pandemic mitigation efforts would be substantial